ABN: 89 609 406 911



ASX Announcement

2 October 2020

Results of General Meeting

Creso Pharma Limited (ASX:CPH) ('Creso Pharma' or **'the Company')** today held a General Meeting of Members from the offices of Azalea Consulting Pty Ltd, Suite 5 CPC, 145 Stirling Highway, Nedlands WA 6009.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the General Meeting is set out in the Annexure which accompanies this release.

Ends

Authority and Contact Details

This announcement has been authorised for release by Erlyn Dale, Joint Company Secretary.

For further information, please contact:

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Media Enquiries

Ben Jarvis | Six Degrees Group E: ben.jarvis@sdir.com.au P: +61 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Disclosure of Proxy Votes

Creso Pharma Limited

Extraordinary General Meeting Friday, 02 October 2020



GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Ratification of prior issue of Tranche 2 Placement Shares	Р	37,487,294	34,579,438 92.24%	1,288,771 3.44%	113,009	1,619,085 4.32%	36,711,514 96.61%	1,288,771 3.39%	115,009
2 Ratification of prior issue of Tranche 1 Placement Shares	Р	37,445,627	34,586,438 92.36%	1,245,104 3.33%	113,009	1,614,085 4.31%	36,713,514 96.72%	1,245,104 3.28%	115,009
3 Issue of Shares to Dr Miri Halperin Wernli — Participation in Placement	Р	24,697,294	21,524,926 87.15%	1,556,702 6.30%	103,009	1,615,666 6.54%	23,653,583 93.83%	1,556,702 6.17%	105,009
4 Issue of Shares to Mr Adam Blumenthal – Participation in Placement	Р	29,288,077	26,116,538 89.17%	1,555,872 5.31%	103,839	1,615,667 5.52%	28,245,196 94.78%	1,555,872 5.22%	105,839
5 Ratification of prior issue of Service Shares	Р	37,501,007	32,118,121 85.65%	4,066,841 10.84%	99,296	1,316,045 3.51%	33,949,157 89.30%	4,066,841 10.70%	99,296
6 Ratification of prior issue of Debt Conversion Shares	Р	37,504,007	34,934,561 93.15%	1,253,401 3.34%	96,296	1,316,045 3.51%	36,765,597 96.70%	1,253,401 3.30%	96,296
7 Ratification of prior issue of Mernova Shares	Р	37,504,837	34,901,521 93.06%	1,272,271 3.39%	95,466	1,331,045 3.55%	36,747,557 96.65%	1,272,271 3.35%	95,466

			Proxy Votes				Poll Results		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Approval to issue future Placement Shares	Р	37,524,346	34,364,639 91.58%	1,530,888 4.08%	76,956	1,628,819 4.34%	36,508,449 95.98%	1,530,888 4.02%	76,956
9 Approval to issue Shares to L1 Capital	Р	37,485,827	32,653,493 87.11%	3,218,018 8.58%	118,275	1,614,316 4.31%	34,782,800 91.53%	3,218,018 8.47%	118,275